252 related articles for article (PubMed ID: 12105835)
21. [Antisecretory drugs, hypergastrinemia and hyperplasia of enterochromaffin-like cells (ECL)].
Andriulli A; Mangia A; Lawson F
Minerva Gastroenterol Dietol; 1991; 37(3):135-40. PubMed ID: 1686409
[TBL] [Abstract][Full Text] [Related]
22. Argyrophil cell hyperplasia and a carcinoid tumour in the stomach of a patient with sporadic Zollinger-Ellison syndrome.
Feurle GE
Gut; 1994 Feb; 35(2):275-7. PubMed ID: 8307483
[TBL] [Abstract][Full Text] [Related]
23. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion.
Gilligan CJ; Lawton GP; Tang LH; West AB; Modlin IM
Am J Gastroenterol; 1995 Mar; 90(3):338-52. PubMed ID: 7872269
[TBL] [Abstract][Full Text] [Related]
24. Histopathology of the gastric oxyntic mucosa in two different patient groups during long-term treatment with omeprazole.
Hage E; Hendel L; Gustafsen J; Hendel J
Eur J Gastroenterol Hepatol; 2003 Jul; 15(7):781-9. PubMed ID: 12811309
[TBL] [Abstract][Full Text] [Related]
25. Expression of vesicular monoamine transporters in endocrine hyperplasia and endocrine tumors of the oxyntic stomach.
Eissele R; Anlauf M; Schäfer MK; Eiden LE; Arnold R; Weihe E
Digestion; 1999; 60(5):428-39. PubMed ID: 10473967
[TBL] [Abstract][Full Text] [Related]
26. Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome.
Lee L; Ramos-Alvarez I; Ito T; Jensen RT
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31623145
[TBL] [Abstract][Full Text] [Related]
27. Time-dependent changes in enterochromaffin-like cell kinetics in stomach of hypergastrinemic rats.
Håkanson R; Tielemans Y; Chen D; Andersson K; Mattsson H; Sundler F
Gastroenterology; 1993 Jul; 105(1):15-21. PubMed ID: 8514032
[TBL] [Abstract][Full Text] [Related]
28. Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffinlike-cell carcinoids in the rat.
Mattsson H; Havu N; Bräutigam J; Carlsson K; Lundell L; Carlsson E
Gastroenterology; 1991 Feb; 100(2):311-9. PubMed ID: 1985029
[TBL] [Abstract][Full Text] [Related]
29. Gastric enterochromaffin-like cell changes in multiple endocrine neoplasia type 1.
Manoharan J; Anlauf M; Albers MB; Denzer UW; Mintziras I; Wächter S; Di Fazio P; Bollmann C; Bartsch DK
Clin Endocrinol (Oxf); 2021 Sep; 95(3):439-446. PubMed ID: 33506527
[TBL] [Abstract][Full Text] [Related]
30. Morphometry of gastric endocrine cells in hypergastrinemic patients treated with the somatostatin analogue octreotide.
Bordi C; Azzoni C; Pilato FP; Robutti F; D'Ambra G; Caruana P; Rindi G; Corleto VD; Annibale B; Delle Fave G
Regul Pept; 1993 Sep; 47(3):307-18. PubMed ID: 8234912
[TBL] [Abstract][Full Text] [Related]
31. The consequences of hypergastrinemia.
Creutzfeldt W
Yale J Biol Med; 1994; 67(3-4):181-94. PubMed ID: 7502528
[TBL] [Abstract][Full Text] [Related]
32. Sampling strategies for analysis of enterochromaffin-like cell changes in Zollinger-Ellison syndrome.
Bordi C; Azzoni C; Ferraro G; Corleto VD; Gibril F; Delle Fave G; Lubensky IA; Venzon DJ; Jensen RT
Am J Clin Pathol; 2000 Sep; 114(3):419-25. PubMed ID: 10989643
[TBL] [Abstract][Full Text] [Related]
33. Gastric endocrine cells in omeprazole-treated and untreated patients with the Zollinger-Ellison syndrome.
Bardram L; Thomsen P; Stadil F
Digestion; 1986; 35 Suppl 1():116-22. PubMed ID: 3792668
[TBL] [Abstract][Full Text] [Related]
34. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome.
Pisegna JR; Norton JA; Slimak GG; Metz DC; Maton PN; Gardner JD; Jensen RT
Gastroenterology; 1992 Mar; 102(3):767-78. PubMed ID: 1537514
[TBL] [Abstract][Full Text] [Related]
35. Gastric carcinoids in patients with hypergastrinemia.
Jordan PH; Barroso A; Sweeney J
J Am Coll Surg; 2004 Oct; 199(4):552-5. PubMed ID: 15454137
[TBL] [Abstract][Full Text] [Related]
36. Pathology of endocrine cells in gastric mucosa.
Bordi C; Ravazzola M; de Vita O
Ann Pathol; 1983; 3(1):19-28. PubMed ID: 6838707
[TBL] [Abstract][Full Text] [Related]
37. The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells.
Maton PN; Lack EE; Collen MJ; Cornelius MJ; David E; Gardner JD; Jensen RT
Gastroenterology; 1990 Oct; 99(4):943-50. PubMed ID: 1697548
[TBL] [Abstract][Full Text] [Related]
38. Hyperplastic, dysplastic, and neoplastic enterochromaffin-like-cell proliferations of the gastric mucosa. Classification and histogenesis.
Solcia E; Fiocca R; Villani L; Luinetti O; Capella C
Am J Surg Pathol; 1995; 19 Suppl 1():S1-7. PubMed ID: 7762735
[TBL] [Abstract][Full Text] [Related]
39. Hypergastrinemia Expands Gastric ECL Cells Through CCK2R
Sheng W; Malagola E; Nienhüser H; Zhang Z; Kim W; Zamechek L; Sepulveda A; Hata M; Hayakawa Y; Zhao CM; Chen D; Wang TC
Cell Mol Gastroenterol Hepatol; 2020; 10(2):434-449.e1. PubMed ID: 32330731
[TBL] [Abstract][Full Text] [Related]
40. Carcinogenic hypergastrinemia: signet-ring cell carcinoma in a patient with multiple endocrine neoplasia type 1 with Zollinger-Ellison's syndrome.
Schott M; Sagert C; Willenberg HS; Schinner S; Ramp U; Varro A; Raffel A; Eisenberger C; Zacharowski K; Perren A; Scherbaum WA
J Clin Endocrinol Metab; 2007 Sep; 92(9):3378-82. PubMed ID: 17609302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
